Objective To explore and observe the clinicalal effect and side effect of patients with recurrent non-Hodgkin lymphoma (NHL) treated by rituximab in combination of CHOP regimen.Methods 20 cases of patients with recurrent non-Hodgkin lymphoma were treated with rituximab in combination of CHOP regimen.Rituximab 375 mg/m2,intravenous drip,dl; isosfamide 1.5 g/m2,intravenous drip,d2~4.21~28 d in one cycle,evaluated clinical effect and side effect of each patients who were treated at least 2 cycles therapy.Results In 20 cases,CR 6 cases (30.0%),PR 7 cases (35.0%),NC 3 cases (15.0%),PD 4 cases (20.0%),totally clinicalal effective proportion was 65.0%(13/20).Major side effect was bone marrow suppression,main expression included neutropenia and thrombocytopenia,lesser expression included nausea and vomiting,toxicity in heart,liver,kidney,nerve and mucosa inflammation.Follow-up visited patients until August,2012,mediam survival time was 14 months.Conclusion Rituximab in combination of CHOP regimen can used as clinical therapy of recurrent non-Hodgkin lymphoma.